The U.S. FDA granted breakthrough device designation to Mursla Bio Ltd.'s Evoliver. The biopsy blood test uses extracellular vesicles to survey hepatocellular carcinoma in high-risk cirrhotic patients ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6, testing ivonescimab in combination with ...

A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the University of Michigan have ...

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders ...

They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new ...

Growth in the first quarter for Boston Scientific Corp.’s blockbuster products, Farapulse and Watchman, pushed the company well over analysts’ expectations and gave management confidence to raise its ...

In all practicality, U.S. FDA Commissioner Marty Makary’s recently announced policy directive removing industry ...

Bioxodes SA is gearing up fundraising for a follow-up study to the newly released interim phase IIa results of its lead asset in treating intracerebral hemorrhagic stroke. Data from the first 16 ...

Just simply getting old, from age 50 to 75, increased risk for Alzheimer’s disease by 100-fold, which really dwarfed 10-fold ...

AMT Medical BV raised $25 million in a series B financing round for its Excimer Laser Assisted Non-Occlusive Anastomosis ...

Named after Swiss mountains, Granite Bio AG emerged from stealth with $70 million in funds through a series B to advance two ...

The BioWorld Biopharmaceutical Index reached a first quarter (Q1) peak of 9.64% by the end of February, before closing March ...